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Strains of the genus Biﬁdobacterium are frequently used as probiotics, for which the absence of acquired antimicrobial resistance
has become an important safety criterion. This clariﬁes the need for antibiotic susceptibility data for biﬁdobacteria. Based on a
recently published standard for antimicrobial susceptibility testing of biﬁdobacteria with broth microdilution method, the range
of susceptibility to selected antibiotics in 117 animal biﬁdobacterial strains was examined. Narrow unimodal MIC distributions
either situated at the low-end (chloramphenicol, linezolid, and quinupristin/dalfopristin) or high-end (kanamycin, neomycin)
concentration range could be detected. In contrast, the MIC distribution of trimethoprim was multimodal. Data derived from
this study can be used as a basis for reviewing or verifying present microbiologicalbreakpoints suggested by regulatory agencies to
assess the safety of these micro-organisms intended for the use in probiotics.
1.Introduction
Probiotics are generally deﬁned as “live micro-organisms
which confer a health beneﬁt on the host when administered
in adequate amounts” [1]. There is considerable interest in
probiotics for a variety of medical conditions, and millions
of people around the world consume probiotic medications
or foods daily for perceived health beneﬁts [2]. Next to
lactobacilli, members of the genus Biﬁdobacterium (B.)a r e
frequently incorporated in probiotic products [3]. Although
they have generally been regarded as safe (GRAS), there
are theoretical concerns regarding their safety [2]. These
concernsincludethe potential for transmigration and conse-
quently the occurrence of diseases [2]. Hence, biﬁdobacteria
have already been isolated from various clinical samples
and reported as potential pathogens [4, 5]. Additionally,
the potential transfer of antibiotic resistance genes from
probiotic bacteria to commensals or potential pathogens
within the gastrointestinal ﬂora is taken very seriously [6, 7].
Thus, microorganisms used as probiotics for humans or
additives in animal nutrition should not contain transfer-
able antimicrobial resistance determinants [8–10]. Hence,
the Panel on Additives and Products or Substances Used
in Animal Feed (FEEDAP) of the European Food Safety
Authority (EFSA) has deﬁned criteria for the assessment
of antimicrobial resistance of bacterial strains used as feed
additives [11]. According to this panel, all bacteria intended
for use as feed additives in Europe must be examined to
ensure the susceptibility of the component strains to a
relevant range of antibiotics [11]. Additionally, EFSA has
proposed the use of the Qualiﬁed Presumption of Safety
(QPS) status as a safety assessment tool for microorganisms
added to food and feed. Within the QPS approach, which
is a system similar in concept and purpose to the GRAS
deﬁnition used in the USA, but modiﬁed to take account
of diﬀerent regulatory practices in Europe, the absence of
acquired antibiotic resistance traits has to be conﬁrmed for
all strains of species with QPS status [12, 13].2 Chemotherapy Research and Practice
In contrast to bacteria with clinical signiﬁcance, standard
procedures and breakpoints have been poorly validated
for antimicrobial susceptibility testing of non pathogenic
bacteria [14]. Because of missing standardized protocols and
susceptibility data for lactic acid bacteria and biﬁdobacteria,
risk assessment of these industrially important bacteria has
been complicated in the past. The development of the lactic
acid bacteria susceptibility test medium [15]p r o v e dt ob ea
ﬁrst major step forward to establish a standardized method
for lactic acid bacteria and biﬁdobacteria. Meanwhile, this
medium has been frequently applied for antimicrobial
susceptibility testing of biﬁdobacteria [16–20]. Based on the
use of this medium, standard operating procedures for
antimicrobial susceptibility testing of biﬁdobacteria have
been proposed [21] and were recently made available as ISO
10932/IDF 233 standard [22].
The occurrence of antimicrobial resistance in animal
strains of B. animalis, B. pseudolongum, and B. thermo-
philum to seven antibiotics (i.e., ampicillin, clindamycin,
erythromycin, gentamicin, streptomycin, tetracycline, and
vancomycin) has been already determined [16, 17]. As up
to 13 antibiotics were proposed by EFSA at the time of
investigation [23], the susceptibility of strains of these
Bifidobacterium species to the remaining antimicrobial
agents chloramphenicol, kanamycin, linezolid, neomycin,
quinupristin/dalfopristin, and trimethoprim was examined
within this study. The obtained data may serve as basis
for the deﬁnition of microbiological breakpoints for biﬁ-
dobacteria. Furthermore, data could be used to eradicate
of biﬁdobacteria from infections, although little is known
about their pathogenic potential [4]. Comparing antimicro-
bial susceptibility data of human and animal strains, which
were tested with the same medium, resistances were more
prevalent in strains of animal origin [24]. The development
of bacterial resistance in livestock may be favored due to
the use of antibiotics throughout whole periods of life and
widely used prophylaxis with medicated feeding stuﬀ at low
doses [25]. Thus, the spread of antimicrobial resistances
in biﬁdobacteria could be better predicted by investigating
animal strains.
2.Materialsand Methods
2.1. Bacterial Strains and Growth Conditions. A total of 112
biﬁdobacteria of animal origin, isolated during the EU
project BIFID (CT-2000-00805) [26], were included in this
study belonging to the species: B. animalis (n = 8), B. pseu-
dolongum (n = 33), and B. thermophilum (n = 71). The
identiﬁcation of the isolates at strain and species level was
previously described by M¨ att¨ oe ta l .[ 16]a n dM a y r h o f e r
et al. [17]. The following BCCM/LMG microbial collection
strains(UniversityGent,Belgium)wereadditionallytestedas
reference microorganisms: B. pseudolongum subsp. globosum
LMG 11569 (ATCC 25865), B. pseudolongum subsp. globo-
sum LMG 11614 (ATCC 25864), B. pseudolongum subsp.
pseudolongum LMG 11594, B. thermophilum LMG 21813
(ATCC25525;typestrain), and B.thermophilumLMG 11574
(ATCC 25866).
Bacteria were maintained at −80◦C, resuscitated in MRS
broth(Oxoid,Hampshire, UK)supplementedwith0.5g/liter
cysteine-HCl (AppliChem, Darmstadt, Germany), and sub-
cultured on the Lactic acid bacteria Susceptibility test
Medium for biﬁdobacteria (LSM-C). This medium consists
of 90% Isosensitest broth (Oxoid), 10% MRS broth (Oxoid),
and 1.5% Agar Bacteriological (Oxoid) supplemented with
0.3g/liter cysteine-HCl (LSM-C) [15]. All incubations were
performed in an anaerobic cabinet (80% N2, 10% CO2 and
10% H2; Scholzen Technik, Switzerland) at 37◦C.
2.2. Antimicrobial Susceptibility Testing. The minimum in-
hibitory concentrations (MICs) of the antimicrobial agents
chloramphenicol, kanamycin, linezolid, neomycin, quin-
upristin/dalfopristin, and trimethoprim were determined by
broth microdilution according to the ISO 10932/IDF 233
standard [22] with minor modiﬁcations. With the exception
of quinupristin/dalfopristin (Sanalog, Kist, Germany) and
linezolid (Pﬁzer, New York, USA), all antibiotics originated
from Sigma-Aldrich (Daint Louis, Missouri, USA). All
antibiotics except for chloramphenicol and trimethoprim
were dissolved in water for preparing stock solutions of
1280µg/mL. To dissolve chloramphenicol 95% ethanol was
needed, whereas 0.05M HCl was required for trimethoprim.
These solvents were used in volumes as low as possible,
and water was ﬁnally added to receive the desired volume
of the stock solution. Subsequently, stock solutions were
diluted in LSM-C broth to obtain solutions with preliminary
concentrations in the range of 0.25–256µg/mL. Of these,
50µl were dispensed in the wells of the microtiter plates.
Bacterial inocula were prepared by suspending colonies
from 48h incubated LSM-C medium to 5mL 0.85% NaCl
solution. Subsequently, inocula were adjusted to McFarland
standard 1 and diluted 1:500 in LSM-C broth for inoc-
ulation of microdilution plates by adding 50µlo fd i l u t e d
inoculum to each well. This resulted in a ﬁnal antibiotic
concentration of 0.12–128µg/mL.
After incubating plates under anaerobic conditions at
37◦C for 48 hours, the MIC value was read as the lowest
concentration of an antimicrobial agent in which visible
growth was inhibited.
The accuracy of susceptibility testing was monitored by
parallel use of the quality control strain Enterococcus faecalis
ATCC 29212.
3.Resultsand Discussion
The antimicrobial susceptibility of 8 B. animalis,3 6B.
pseudolongum,and73B.thermophilumstrains, includingﬁve
reference strains, to chloramphenicol, kanamycin, linezolid,
neomycin, quinupristin/dalfopristin, and trimethoprim is
summarized in Table 1.M I C s( µg/mL) are reported in terms
of the MIC range, MIC50 (MIC that inhibited 50% of the
tested strains), and MIC90 (MIC that inhibited 90% of the
tested strains). Accordingly, no marked diﬀerence in the
MICdistributionsbetweenthediﬀerentspecieswasobserved
for chloramphenicol, kanamycin, linezolid, neomycin, and
quinupristin/dalfopristin. For these antimicrobial agentsChemotherapy Research and Practice 3
Table 1: Susceptibility of 8 B. animalis, 36. B. pseudolongum,a n d7 3B. thermophilum strains to selected antimicrobial agents as determined
by the broth microdilution method using LSM-C medium.
Antibiotic Species MIC (µg/mL)
MIC range MIC50 MIC90
Chloramphenicol B. animalis 2–4 2 4
B. pseudolongum 1-2 1 2
B. thermophilum 0.5–2 1 2
Kanamycin B. animalis >128 >128 >128
B. pseudolongum ≥128 >128 >128
B. thermophilum ≥128 >128 >128
Linezolid B. animalis 0.5–2 1 2
B. pseudolongum 0.5–2 1 1
B. thermophilum 0.5–1 0.5 1
Neomycin B. animalis 32–>128 64 >128
B. pseudolongum 16–>128 64 >128
B. thermophilum 16–>128 128 >128
Quinupristin/ B. animalis ≤0.12 ≤0.12 ≤0.12
Dalfopristin B. pseudolongum ≤0.12–0.25 ≤0.12 0.25
B. thermophilum ≤0.12–0.25 ≤0.12 0.25
Trimethoprim B. animalis ≤0.12 ≤0.12 ≤0.12
B. pseudolongum ≤0.12–32 ≤0.12 4
B. thermophilum 0.5–>128 8 128
MIC50 and MIC90:M I C s( µg/mL) that inhibited 50% and 90% of the number of strains tested, respectively.
narrow unimodal MIC distributions either at the low-end
concentrationrange(i.e.,forchloramphenicol,linezolid,and
quinupristin/dalfopristin) or at the high-end concentration
range (i.e., for kanamycin and neomycin) were determined
(Figures 1(a)–1(e)). A unimodal distribution describes a
population, which is either uniformly susceptible (i.e., for
chloramphenicol, linezolid, and quinupristin/dalfopristin)
or resistant (i.e., for kanamycin and neomycin) [27, 28].
Next to a unimodal distribution MIC values, obtained by
susceptibility testing of a deﬁned population of strains,
can also follow a bimodal or multimodal distribution [29].
For trimethoprim a multimodal distribution with three
diﬀerent subpopulations was identiﬁed: one with very low
MICs (≤0.12µg/mL), another one with higher MICs (0.5–
16µg/mL), and a last one with high MICs (32–>128µg/mL)
(Figure 1(f)). While B. animalis strains generally had lower
trimethoprim MICs (≤0.12µg/mL), the highest MICs were
detected for B. thermophilum strains (0.5–>128µg/mL).
The MIC values of B. pseudolongum strains were between
≤0.12µg/mL and 32µg/mL.
In order to allow the interpretation of antimicrobial
susceptibility proﬁles of biﬁdobacteria used in food and
feed applications, microbiological breakpoints are needed
for categorizing susceptible or resistant strains. Especially
bimodal distributions of MIC values play an important
role in determining the microbiological breakpoint. Nev-
ertheless, also unimodal and multimodal distributions can
support the deﬁnition of microbiological breakpoints to
distinguish strains with acquired resistance from the native,
susceptible population. Beside this, MICs for determining
microbiological breakpoints are only meaningful when the
methods and conditions of the test are known [30]. It is for
thisreasonthatthedevelopmentofaninternationalstandard
reference method for determining MICs for biﬁdobacteria
was recently proposed [22]. Thus, data obtained in this
study, following the newest method developments con-
cerning antimicrobial susceptibility testing of biﬁdobacteria,
can be used as a basis for reviewing or verifying present
microbiological breakpoints for biﬁdobacteria to assess the
safety of microorganisms intended for use in food and feed
applications.
According to the literature, biﬁdobacteria are usually
sensitive to chloramphenicol. Normal MICs to this antimi-
crobial agent using various test techniques and media have
been reported to range between 0.5 and 8µg/mL [31–37].
Only once in the literature, ﬁve strains belonging to the
species B. infantis, B. longum, and B. suis as well as one
Biﬁdobacterium sp. isolate with higher MICs up to 64µg/mL
were detected by Kheadr et al. [38]. However, these authors
concluded that the strains may still be sensitive. Thus,
strains with acquired resistance have not been detected until
now. Using the recommended LSM-C medium [22]a n d
the same [20] or similar conditions [19] for antimicrobial
susceptibility testing, a chloramphenicol MIC ≤2µg/mL for
one B. thermophilum strain [19] or MICs between 1 and
2µg/mL for ten B. longum strains [20] could be observed.
As only a small number of strains were tested within the
above-mentioned studies, the widening of the MIC distri-
bution from 0.5 to 4µg/mL (Figure 1(a)) by investigating4 Chemotherapy Research and Practice
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Figure 1: Distribution of minimuminhibitory concentrations (MICs) for (a) chloramphenicol,(b) kanamycin,(c) linezolid, (d) neomycin,
(e) quinupristin/dalfopristin, and (f) trimethorpim in 8 B. animalis, 36. B. pseudolongum, and 73 B. thermophilum strains as determined
with the microdilution broth method using LSM-C medium.
more than 100 strains in this study is obvious. Applying
the recommended breakpoint of EFSA [11], all strains of
the unimodal distribution are categorized as susceptible,
approving the recent EFSA microbiological breakpoint for
chloramphenicol.
Most biﬁdobacteria have been reported as resistant to
aminoglycosidesbecauseofthelackofcytochrome-mediated
drug transport system, resulting in a failure of the drug
to reach its target [39]. The resistance of the tested strains
to gentamicin and streptomycin has already been reported
before [16, 17]. Correspondingly, all strains were resistant
to kanamycin (128–>128µg/mL, Figure 1(b)) and neomycin
(16–>128µg/mL, Figure 1(d)). The particular resistance of
biﬁdobacteria to kanamycin is well known, and MICs
between 64 and >1024µg/mL were described for this
antimicrobialagent,whereasforneomycinMICslaybetween
16 and >1024µg/mL testing a large number of species
such as B. biﬁdum, B. breve, B. catenulatum, B. infantis, B.
longum, B. suis, B. thermophilum, and others [32, 35–37].
Using the LSM-C medium, the antimicrobial susceptibility
to kanamycin was only tested by Kushiro et al. [20]a n d
Klose et al. [19]. Whereas Kushiro et al. [20] received MICs
between 128 and 512µg/mL for ten B. longum strains, the
tested B. thermophilum strain of Klose et al. [19]d i s p l a y e d
an MIC value of 64µg/mL. The lower MIC value detected
by Klose et al. may be due to other testing conditions (i.e.,
24 hours instead of 48 hours of incubation), underlining the
importance of controlled and standardized conditions for
susceptibility testing [40]. While breakpoints for gentamicin
and streptomycin are indicated in the EFSA document [11],
none is required for kanamycin or speciﬁed for neomycin.
Low level, unimodal MIC distributions between 0.5
and 1µg/mL have been reported for linezolid and diﬀerent
biﬁdobacterial species, suggesting all biﬁdobacteria are sus-
ceptibleto thisantibiotic [37, 41]. This is in good accordance
with our results, since all tested strains were inhibited by
a linezolid concentration lower than 4µg/mL (Figure 1(c)).
Ten B. longum strains, also tested using the same medium
and conditions, displayed MIC values of 0.5 and 1µg/mL
[20]. As the nonmutational resistance to linezolid, which
is due to the acquisition of the cfr gene, is extremely rare
and also confers resistance to chloramphenicol [42, 43],
testing for this antimicrobial agent was no longer considered
as relevant by EFSA [11]. Checking for chloramphenicol
resistance should eﬃciently cover the hazard of an acquired
resistance to linezolid [11].
The in vitro susceptibility of biﬁdobacteria to quinu-
pristindalfopristin has been rarely studied. Only two pre-
vious reports showed that biﬁdobacteria are susceptible
to this semisynthetic mixture by testing 100 strains of 11Chemotherapy Research and Practice 5
biﬁdobacterial species by agar overlay disc diﬀusion [18]
and one B. thermophilum strain by broth microdilution [19]
using the same test medium (LSM-C). The obtained MIC
value of 0.5 µg/mL by Klose et al. [19] was one dilution
stephigherthan theMICrange(≤0.12–0.25µg/mL)received
within this study (Figure 1(e)). The EFSA breakpoint of
1µg/mLtoquinupristin-dalfopristinappearstobeapplicable
for biﬁdobacteria [11].
Reduced susceptibility of biﬁdobacteria towards trime-
thoprim was described by Ouoba et al. [37]. Susceptibility
was also found to be variable and strain-speciﬁc by Masco
et al. investigating 100 strains of 11 biﬁdobacterial species
[18]o rt ob e≥32 µg/mL by Kushiro et al. testing 10 B.
longum strains [20], also using the same medium as within
thisstudy.Hence,avariablebutspecies-speciﬁcsusceptibility
was detected, nearly covering the whole concentration range
tested (Figure 1(f)). Also a wide range of trimethoprim
MICs with no clear breakpoint values was identiﬁed for
certain Lactobacillus species [44]. This was led back to
the presence of antagonistic components in the medium,
complicating susceptibility testing concerning trimethoprim
[11, 15]. Thus, MIC testing of trimethoprim was no longer
considered as relevant by EFSA [11].
4.Conclusion
In this study, the recently published ISO 10932/IDF 233
standard [22] was used to provide susceptibility data on the
basis of a representative number of animal biﬁdobacteria.
These data could be used for reviewing or verifying present
microbiologicalbreakpointssuggestedbyregulatoryagencies
to assess the safety of microorganisms intended for the
use in probiotics. Nevertheless, more data including MIC
valuesofhumanbiﬁdobacteriafortheseantimicrobialagents
applying the same testing conditions are needed to obtain
adequate breakpoints for diﬀerentiating susceptible bacteria
from those with acquired resistance. Additionally, a broad
screening of resistance genes using molecular tools would
also be of importance for the deﬁnition of applicable
breakpoints.
Acknowledgements
This study was performed as a part of the EU Project
“ACE-ART” (CT-2003-506214) within the 6th framework.
Franc ¸oise Gavini and Matthias Upmann are gratefully
acknowledged for providing the strains isolated in the EU
Project “BIFID” (CT-2000-00805). Pﬁzer is thanked for
providing linezolid.
References
[1] FAO/WHO, “Health and nutritional properties of probiotics
in food including powder milk with live lactic acid bacteria,”
Report of a Joint FAO/WHO Expert Group, Cordoba,
Argentina, Food and Agricultural Organization of the United
Nations, World Health Organization, 2001, http://www.who.
int/foodsafety/publications/fs management/en/probiotics.pdf.
[ 2 ]D .R .S n y d m a n ,“ T h es a f e t yo fp r o b i o t i c s , ”Clinical Infectious
Diseases, vol. 46, no. 2, supplement, pp. S104–S111, 2008.
[ 3 ]S .C .L e a h y ,D .G .H i g g i n s ,G .F .F i t z g e r a l d ,a n dD .V a n
Sinderen, “Getting better with biﬁdobacteria,” Journal of
Applied Microbiology, vol. 98, no. 6, pp. 1303–1315, 2005.
[4] I. Brook, “Isolation of non-sporing anaerobic rods from
infections in children,” Journal of Medical Microbiology,v o l .
45, no. 1, pp. 21–26, 1996.
[5] I. Brook, “Pericarditis caused by anaerobic bacteria,” Interna-
tional Journal of Antimicrobial Agents, vol. 33, no. 4, pp. 297–
300, 2009.
[6] M. Teuber, L. Meile, and F. Schwarz, “Acquired antibiotic
resistance in lactic acid bacteria from food,” Antonie van
Leeuwenhoek, vol. 76, no. 1–4, pp. 115–137, 1999.
[7] V. Vankerckhoven, G. Huys, M. Vancanneyt et al., “Biosafety
assessment of probiotics used for human consumption:
recommendations from the EU-PROSAFE project,” Trends in
Food Science and Technology, vol. 19, no. 2, pp. 102–114, 2008.
[8] FAO/WHO, “Guidelines for the evaluation of probiotics in
food,” Food Agriculture Organization of the United Nations
and World Health Organization Working Group Report,
London,Canada, pp. 1–11, 2002.
[9] A.H enriksson,T .Bor od y ,andR.Clancy ,“Pr obioticsunderthe
regulatory microscope,” Expert Opinion on Drug Safety,v o l .4 ,
no. 6, pp. 1135–1143, 2005.
[10] A. von Wright, “Regulating the safety of probiotics - The
European approach,” Current Pharmaceutical Design, vol. 11,
no. 1, pp. 17–23, 2005.
[11] EFSA (European Food Safety Authority), “Update of the
criteria used in the assessment of bacterial resistance to
antibiotics of human and veterinary importance,” The EFSA
Journal, vol. 732, pp. 1–15, 2008.
[12] EFSA (European Food Safety Authority), “EFSA scientiﬁc
colloquium summary report: QPS—qualiﬁed presumption of
safety of microorganisms in food and feed,” 2004, http://
www.efsa.europa.eu/en/colloquiareports/colloquiaqps.htm.
[13] EFSA (European Food Safety Authority), “Opinion of the
Scientiﬁc Committee on a request from EFSA on the intro-
duction of a Qualiﬁed Presumption of Safety (QPS) approach
for assessment of selected microorganisms referred to EFSA,”
The EFSA Journal, vol. 587, pp. 1–16, 2007.
[14] J. M¨ att¨ o, M. L. Suihko, and M. Saarela, “Comparison of
three test media for antimicrobial susceptibility testing of
biﬁdobacteria using the Etest method,” International Journal
of Antimicrobial Agents, vol. 28, no. 1, pp. 42–48, 2006.
[15] I. Klare, C. Konstabel, S. M¨ uller-Bertling et al., “Evaluation
of new broth media for microdilution antibiotic susceptibility
testing of lactobacilli, pediococci, lactococci, and biﬁdobacte-
ria,” Applied and Environmental Microbiology, vol. 71, no. 12,
pp. 8982–8986, 2005.
[16] J. M¨ att¨ o, A. H. A. M. van Hoek, K. J. Domig et al., “Suscepti-
bility of human and probiotic Biﬁdobacterium spp. to selected
antibiotics as determined by the Etest method,” International
Dairy Journal, vol. 17, no. 9, pp. 1123–1131, 2007.
[17] S. Mayrhofer, K. J. Domig, E. Amtmann et al., “Antibiotic
susceptibility of Biﬁdobacterium thermophilum and Biﬁdobac-
terium pseudolongum isolates from animal sources,” Journal of
Food Protection, vol. 70, no. 1, pp. 119–124, 2007.
[ 1 8 ]L .M a s c o ,K .V a nH o o r d e ,E .D eB r a n d t ,J .S w i n g s ,a n dG .
Huys, “Antimicrobial susceptibility of Biﬁdobacterium strains
from humans, animals and probiotic products,” Journal of
Antimicrobial Chemotherapy, vol. 58, no. 1, pp. 85–94, 2006.
[19] V. Klose, R. Bruckbeck, S. Henikl, G. Schatzmayr, and A.
P. Loibner, “Identiﬁcation and antimicrobial susceptibility6 Chemotherapy Research and Practice
of porcine bacteria that inhibit the growth of Brachyspira
hyodysenteriae in vitro,” Journal of Applied Microbiology,v o l .
108, no. 4, pp. 1271–1280, 2010.
[20] A. Kushiro, C. Chervaux, S. Cools-Portier et al., “Antimicro-
bial susceptibility testing of lactic acid bacteria and biﬁdobac-
teria by broth microdilution method and Etest,” International
Journal of Food Microbiology, vol. 132, no. 1, pp. 54–58, 2009.
[21] G. Huys, K. D’Haene, M. Cnockaert et al., “Intra- and inter-
laboratory performances of two commercial antimicrobial
susceptibility testing methods for biﬁdobacteria and nonen-
terococcal lactic acid bacteria,” Antimicrobial Agents and
Chemotherapy, vol. 54, no. 6, pp. 2567–2574, 2010.
[22] ISO (International Organization for Standardization), “Milk
and milk products—determination of the minimal inhibitory
concentration (MIC) of antibiotics applicable to biﬁdobac-
teria and non-enterococcal lactic acid bacteria (LAB),” ISO
10932/IDF 233 standard, 2010.
[23] EFSA (European Food Safety Authority), “Opinion of the
Scientiﬁc Panel on Additives and Products orSubstances Used
in AnimalFeed (FEEDAP) on theupdating ofthe criteria used
inassessmentofbacteria forresistancetoantibioticsofhuman
andveterinary importance,” TheEFSAJournal, vol.223,pp.1–
12, 2005.
[ 2 4 ]B .M a y o ,S .M a y r h o f e r ,S .D e l g a d o ,a n dK .J .D o m i g ,“ A n t i b i -
otic resistance/susceptibility proﬁles of biﬁdobacteria and
molecular analysis of atypical resistances,” in Biﬁdobacteria—
Genomicsand MolecularAspects,B.MayoandD.vanSinderen,
Eds., pp. 195–215, Caister Academic Press, Norwich, UK,
2010.
[25] F. R. Ungemach, “Figures on quantities of antibacterials used
fordiﬀerent purposes in the EU countries andinterpretation,”
Acta veterinaria Scandinavica. Supplementum, vol. 93, pp. 89–
97, 2000.
[26] F. Gavini, V. Delcenserie, K. Kopeinig et al., “Biﬁdobacterium
species isolated from animal feces and from beef and pork
meat,” Journal of Food Protection, vol. 69, no. 4, pp. 871–877,
2006.
[27] F. Goldstein, C. J. Soussy, and A. Thabaut, “Deﬁnition of the
clinical antibacterial spectrum of activity,” Clinical Microbiol-
ogyand Infection,vol.2,no.1,supplement,pp. S40–S45,1996.
[28] J. Sirot, P. Courvalin, and C. J. Soussy, “Deﬁnition and
determination of in vitro antibiotic susceptibility breakpoints
for bacteria,” Clinical Microbiology and Infection,v o l .2 ,n o .1 ,
supplement, pp. S5–S10, 1996.
[29] J. W. Mouton, “Breakpoints: current practice and future
perspectives,” International Journal of Antimicrobial Agents,
vol. 19, no. 4, pp. 323–331, 2002.
[30] J.TurnidgeandD.L.Paterson,“Settingandrevisingantibacte-
rial susceptibility breakpoints,” Clinical Microbiology Reviews,
vol. 20, no. 3, pp. 391–408, 2007.
[31] M. S. Ammor, A. B. Fl´ o r e z ,A .H .A .M .v a nH o e ke t
al., “Molecular characterization of intrinsic and acquired
antibiotic resistance in lactic acid bacteria and biﬁdobacteria,”
Journal of Molecular Microbiology and Biotechnology, vol. 14,
no. 1–3, pp. 6–15, 2007.
[32] M. R. D’Aimmo, M. Modesto, and B. Biavati, “Antibiotic
resistance of lactic acid bacteria and Biﬁdobacterium spp. iso-
lated from dairy and pharmaceutical products,” International
Journal of Food Microbiology, vol. 115, no. 1, pp. 35–42, 2007.
[33] S. Delgado, A. B. Fl´ orez, and B. Mayo, “Antibiotic suscepti-
bility of Lactobacillus and Biﬁdobacterium species from the
human gastrointestinal tract,” Current Microbiology, vol. 50,
no. 4, pp. 202–207, 2005.
[34] S. Delgado, E. O’Sullivan, G. Fitzgerald, and B. Mayo, “In
vitroevaluationoftheprobioticproperties ofhumanintestinal
Biﬁdobacterium species and selection of new probiotic can-
didates,” Journal of Applied Microbiology, vol. 104, no. 4, pp.
1119–1127, 2008.
[35] K. S. Lim, C. S. Huh, and Y. J. Baek, “Antimicrobial suscepti-
bility ofbiﬁdobacteria,” Journal of Dairy Science,v ol.76,no .8,
pp. 2168–2174, 1993.
[36] D. Matteuzzi, F. Crociani, and P. Brigidi, “Antimicrobial
susceptibility of Biﬁdobacterium,” Annales de Microbiologie
(Paris), vol. 134, no. 3, pp. 339–349, 1983.
[37] L. I. I. Ouoba, V. Lei, and L. B. Jensen, “Resistance of potential
probiotic lactic acid bacteria and biﬁdobacteria of African
and European origin to antimicrobials: determination and
transferability of the resistance genes to other bacteria,”
International Journal of Food Microbiology, vol. 121, no. 2, pp.
217–224, 2008.
[38] E. Kheadr, N. Bernoussi,C. Lacroix,and I. Fliss,“Comparison
of the sensitivity of commercial strains and infant isolates of
biﬁdobacteria to antibiotics and bacteriocins,” International
Dairy Journal, vol. 14, no. 12, pp. 1041–1053, 2004.
[39] L. E. Bryan, S. K. Kowand, and H. M. Van den Elzen,
“Mechanism of aminoglycoside antibiotic resistance in anaer-
obic bacteria: Clostridium perfringens and Bacteroides fragilis,”
Antimicrobial Agents and Chemotherapy, vol. 15, no. 1, pp. 7–
13, 1979.
[40] M. Egerv¨ arn,H .Lind mar k,S.R oos,G .H u y s,andS.Lind gr e n,
“Eﬀects of inoculum size and incubation time on broth
microdilution susceptibility testing of lactic acid bacteria,”
Antimicrobial Agents and Chemotherapy,v o l .5 1 ,n o .1 ,p p .
394–396, 2007.
[ 4 1 ]C .M o u b a r e c k ,F .G a v i n i ,L .V a u g i e n ,M .J .B u t e l ,a n dF .
Doucet-Populaire, “Antimicrobial susceptibility of biﬁdobac-
teria,” Journal of Antimicrobial Chemotherapy, vol. 55, no. 1,
pp. 38–44, 2005.
[42] C. A. Arias, M. Vallejo, J. Reyes et al., “Clinical and microbio-
logical aspects of linezolid resistance mediated by the cfr gene
encoding a 23S rRNA methyltransferase,” Journal of Clinical
Microbiology, vol. 46, no. 3, pp. 892–896, 2008.
[43] S. M.Toh, L.Xiong, C. A. Arias et al.,“Acquisition ofa natural
resistance gene renders a clinicalstrain ofmethicillin-resistant
Staphylococcus aureus resistant to the synthetic antibiotic
linezolid,” Molecular Microbiology, vol. 64, no. 6, pp. 1506–
1514, 2007.
[44] J. M. Korhonen, Y. Sclivagnotis,and A. V. Wright, “Character-
ization of dominant cultivable lactobacilli and their antibiotic
resistance proﬁles from faecal samples of weaning piglets,”
Journal of Applied Microbiology,vol.103,no.6,pp. 2496–2503,
2007.